Highlights

Solutions

Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.

Highlights

Platforms

To accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.

Highlights

Anti-CD33 CAR-T Preclinical in vivo Assay

Our collaborative approach and deep scientific and regulatory understanding of various drug discovery and development solutions helps us shape the best strategy for bringing a novel therapy to market and design custom studies and programs that reduce risk and accelerate timelines.

CONTACT US

Anti-CD33 CAR-T Preclinical in vivo Assay

Target Background

CD33 or Siglec-3 (sialic acid binding immunoglobulin-like lectin 3) is a trans-membrane receptor, consisting of two extracellular immunoglobulin domains and two intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The expression of CD33 is restricted in the myeloid lineage. It is highly expressed on myeloid progenitor cells but much lower on differentiated cells such as tissue macrophages and peripheral granulocytes. In addition, CD33 is highly expressed on, and considered as a marker of acute myeloid leukemia (AML), which is the most common form of leukemia in human. The prognosis of AML is very poor. Several studies have utilized CD33-targeted antibody-drug conjugate (ADC) such as vadastuximab talirine (developed by Seattle Genetics) to induce the lysis of myeloid leukemia cells in vivo.

Anti-CD33 CAR-T Cell Therapy

A preclinical test of anti-CD33 CAR-T cells showed significant effector functions in vitro, and induced reduction of leukemia burden and prolonged survival of AML xenograft murine models. However, the anti-CD33 CAR-T cell treatment resulted in serious hematopoietic toxicity in animal models, suggesting the permanent infusion of anti-CD33 CAR-T cells may yield unacceptable toxicity. Therefore, the novel 4th generation CARs that contain an “off switch” may be used to avoid long-term myelosuppression. Several clinical trials on relapsed and/or chemotherapy refractory CD33+ AML with autologous or allogeneic anti-CD33 CAR-T cells are being conducted. It is reported that adverse effect including fever, pancytopenia and elevated cytokine levels in serum are observed.

To test the in vivo efficacy and safety of anti-CD33 CAR-T cells, SCID mice are injected with different kinds of CD33 positive cells such as MOLM 14 cell line or human primary AML cells via tail veins. Specially, to assess the hematopoietic toxicity of anti-CD33 CAR-T cells, mice employing humanized immune system that is myeloid biased have been used. We are also able to provide non-human primates (NHPs) and rats models.

The therapeutic outcome of anti-CD33 CAR-T cells depends on many factors such as the CAR composition, the transduction method, the subtype and expansion method of T cells. It is essential to determine the efficacy, toxicity, tolerability and bio-distribution characteristics in animal models before clinical trials. With years of experience in developing cell therapy technologies, Creative Biolabs is able to provide a wide range of high-quality services for CAR-T preclinical in vivo assay. Various standardized and customized rodent models and assay systems have been developed. Also, assays in other species, including non-human primates (NHPs) are available.

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.